BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31129148)

  • 21. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
    Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
    Di K; Linskey ME; Bota DA
    Oncogene; 2013 Oct; 32(42):5038-47. PubMed ID: 23178488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
    Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
    Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the insulin-like growth factor-1 receptor induces resistance to epidermal growth factor receptor antagonism in head and neck squamous carcinoma cells.
    Jameson MJ; Beckler AD; Taniguchi LE; Allak A; Vanwagner LB; Lee NG; Thomsen WC; Hubbard MA; Thomas CY
    Mol Cancer Ther; 2011 Nov; 10(11):2124-34. PubMed ID: 21878657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. miR-422a Inhibits Glioma Proliferation and Invasion by Targeting IGF1 and IGF1R.
    Wang H; Tang C; Na M; Ma W; Jiang Z; Gu Y; Ma G; Ge H; Shen H; Lin Z
    Oncol Res; 2017 Jan; 25(2):187-194. PubMed ID: 28277190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo.
    Zhou X; Shen F; Ma P; Hui H; Pei S; Chen M; Wang Z; Zhou W; Jin B
    Mol Med Rep; 2015 Oct; 12(4):5641-6. PubMed ID: 26238593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells.
    Hui AM; Zhang W; Chen W; Xi D; Purow B; Friedman GC; Fine HA
    Cancer Res; 2004 Dec; 64(24):9115-23. PubMed ID: 15604281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
    Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
    Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
    [No Abstract]   [Full Text] [Related]  

  • 31. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
    Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
    Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roscovitine effectively enhances antitumor activity of temozolomide in vitro and in vivo mediated by increased autophagy and Caspase-3 dependent apoptosis.
    Pandey V; Ranjan N; Narne P; Babu PP
    Sci Rep; 2019 Mar; 9(1):5012. PubMed ID: 30899038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
    Wu G; Barth RF; Yang W; Kawabata S; Zhang L; Green-Church K
    Mol Cancer Ther; 2006 Jan; 5(1):52-9. PubMed ID: 16432162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines.
    Friend KE; Khandwala HM; Flyvbjerg A; Hill H; Li J; McCutcheon IE
    Growth Horm IGF Res; 2001 Apr; 11(2):84-91. PubMed ID: 11472074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR inhibitor enhances cisplatin sensitivity of human glioma cells.
    Zhang Y; Xing X; Zhan H; Li Q; Fan Y; Zhan L; Yu Q; Chen J
    J Huazhong Univ Sci Technolog Med Sci; 2011 Dec; 31(6):773-778. PubMed ID: 22173497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells.
    Niu J; Li XN; Qian H; Han Z
    J Cancer Res Clin Oncol; 2008 Apr; 134(4):503-13. PubMed ID: 17901981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
    Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
    J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
    Kim WY; Prudkin L; Feng L; Kim ES; Hennessy B; Lee JS; Lee JJ; Glisson B; Lippman SM; Wistuba II; Hong WK; Lee HY
    Cancer; 2012 Aug; 118(16):3993-4003. PubMed ID: 22359227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
    Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
    Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.